Non-invasive Device-Mediated Brain Drug Delivery across the Blood-Brain Barrier

It is well known that the blood–brain barrier (BBB), substantially composed of tight junctions between the capillary endothelial cells and efflux transporters such as MDR1 at the apical membrane of the capillary endothelial cells, prevents drugs from entering the brain. Accordingly, drug delivery in...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Format: Online
Język:angielski
Wydane: MDPI - Multidisciplinary Digital Publishing Institute 2024
Hasła przedmiotowe:
Dostęp online:ONIX_20240514_9783725806805_428
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
_version_ 1869530294593257472
collection Directory of Open Access Books
description It is well known that the blood–brain barrier (BBB), substantially composed of tight junctions between the capillary endothelial cells and efflux transporters such as MDR1 at the apical membrane of the capillary endothelial cells, prevents drugs from entering the brain. Accordingly, drug delivery into the brain across the BBB is a challenging task, particularly in central nervous system diseases such as Alzheimer’s disease and Parkinson’s disease, as well as brain cancers such as glioma. It is true that drugs in systemic circulation go through intentional membrane disruption or intentional tight junction disruption into the brain across the BBB, but bystander harmful compounds can enter the brain together. Moreover, although craniotomy is often conducted for surgical removal or direct drug administration, this process burdens and torments patients. Thus, non-invasive, device-mediated brain drug delivery across the BBB should be developed to improve not only patient health, but also quality of life. At present, brain drug delivery systems that utilize biological transport machineries such as carrier-mediated transport, receptor-mediated transcytosis, lipid-raft-mediated transcytosis, or macropinocytosis at the BBB have been extensively investigated. This Special Issue aims to share recent progress and trends in this field.
format Online
id doab-20.500.12854ir-137832
institution Directory of Open Access Books
language eng
publishDate 2024
publishDateRange 2024
publishDateSort 2024
publisher MDPI - Multidisciplinary Digital Publishing Institute
publisherStr MDPI - Multidisciplinary Digital Publishing Institute
record_format ojs
spelling doab-20.500.12854ir-1378322024-05-14T14:38:18Z Non-invasive Device-Mediated Brain Drug Delivery across the Blood-Brain Barrier Tournier, Nicolas Tashima, Toshihiko glioblastoma focused ultrasound blood-brain barrier PET SPECT drug delivery rotigotine lecithin-chitosan hybrid nanoparticles intranasal delivery nose-to-brain uptake brain distribution study in vitro model blood–brain barrier (BBB) nanoparticles targeted receptor-mediated transcytosis ligand conjugation nicotinic acetylcholine receptor nanobody VHH transferrin receptor receptor-mediated transcytosis nanoparticle liposome extracellular vesicle chemotherapy targeted therapy blood–brain barrier brain tumor glioma cell-penetrating peptides (CPPs) endosomal entrapment homing peptides tumour-specific markers siRNA-CPP delivery porous silicon nanoparticles BBB-on-a-chip ligand density organ-on-a-chip nanomedicine microfluidic model neurodegenerative disorders non-invasive delivery device-related delivery Alzheimer’s disease Parkinson’s disease ALS Down syndrome CNS disorders nasal delivery biologics nose-to-brain the blood–brain barrier mesenchymal stem cell-based drug delivery transmembrane drug delivery n/a thema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TD Industrial chemistry and manufacturing technologies::TDC Industrial chemistry and chemical engineering::TDCW Pharmaceutical chemistry and technology It is well known that the blood–brain barrier (BBB), substantially composed of tight junctions between the capillary endothelial cells and efflux transporters such as MDR1 at the apical membrane of the capillary endothelial cells, prevents drugs from entering the brain. Accordingly, drug delivery into the brain across the BBB is a challenging task, particularly in central nervous system diseases such as Alzheimer’s disease and Parkinson’s disease, as well as brain cancers such as glioma. It is true that drugs in systemic circulation go through intentional membrane disruption or intentional tight junction disruption into the brain across the BBB, but bystander harmful compounds can enter the brain together. Moreover, although craniotomy is often conducted for surgical removal or direct drug administration, this process burdens and torments patients. Thus, non-invasive, device-mediated brain drug delivery across the BBB should be developed to improve not only patient health, but also quality of life. At present, brain drug delivery systems that utilize biological transport machineries such as carrier-mediated transport, receptor-mediated transcytosis, lipid-raft-mediated transcytosis, or macropinocytosis at the BBB have been extensively investigated. This Special Issue aims to share recent progress and trends in this field. 2024-05-14T14:38:06Z 2024-05-14T14:38:06Z 2024 book ONIX_20240514_9783725806805_428 9783725806805 9783725806799 https://directory.doabooks.org/handle/20.500.12854/137832 eng application/octet-stream Attribution-NonCommercial-NoDerivatives 4.0 International https://mdpi.com/books/pdfview/book/9070 https://mdpi.com/books/pdfview/book/9070 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-7258-0679-9 10.3390/books978-3-7258-0679-9 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783725806805 9783725806799 244 open access
spellingShingle glioblastoma
focused ultrasound
blood-brain barrier
PET
SPECT
drug delivery
rotigotine
lecithin-chitosan hybrid nanoparticles
intranasal delivery
nose-to-brain uptake
brain distribution study
in vitro model
blood–brain barrier (BBB)
nanoparticles
targeted receptor-mediated transcytosis
ligand conjugation
nicotinic acetylcholine receptor
nanobody
VHH
transferrin receptor
receptor-mediated transcytosis
nanoparticle
liposome
extracellular vesicle
chemotherapy
targeted therapy
blood–brain barrier
brain tumor
glioma
cell-penetrating peptides (CPPs)
endosomal entrapment
homing peptides
tumour-specific markers
siRNA-CPP delivery
porous silicon nanoparticles
BBB-on-a-chip
ligand density
organ-on-a-chip
nanomedicine
microfluidic model
neurodegenerative disorders
non-invasive delivery
device-related delivery
Alzheimer’s disease
Parkinson’s disease
ALS
Down syndrome
CNS disorders
nasal delivery
biologics
nose-to-brain
the blood–brain barrier
mesenchymal stem cell-based drug delivery
transmembrane drug delivery
n/a
thema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TD Industrial chemistry and manufacturing technologies::TDC Industrial chemistry and chemical engineering::TDCW Pharmaceutical chemistry and technology
Non-invasive Device-Mediated Brain Drug Delivery across the Blood-Brain Barrier
title Non-invasive Device-Mediated Brain Drug Delivery across the Blood-Brain Barrier
title_full Non-invasive Device-Mediated Brain Drug Delivery across the Blood-Brain Barrier
title_fullStr Non-invasive Device-Mediated Brain Drug Delivery across the Blood-Brain Barrier
title_full_unstemmed Non-invasive Device-Mediated Brain Drug Delivery across the Blood-Brain Barrier
title_short Non-invasive Device-Mediated Brain Drug Delivery across the Blood-Brain Barrier
title_sort non invasive device mediated brain drug delivery across the blood brain barrier
topic glioblastoma
focused ultrasound
blood-brain barrier
PET
SPECT
drug delivery
rotigotine
lecithin-chitosan hybrid nanoparticles
intranasal delivery
nose-to-brain uptake
brain distribution study
in vitro model
blood–brain barrier (BBB)
nanoparticles
targeted receptor-mediated transcytosis
ligand conjugation
nicotinic acetylcholine receptor
nanobody
VHH
transferrin receptor
receptor-mediated transcytosis
nanoparticle
liposome
extracellular vesicle
chemotherapy
targeted therapy
blood–brain barrier
brain tumor
glioma
cell-penetrating peptides (CPPs)
endosomal entrapment
homing peptides
tumour-specific markers
siRNA-CPP delivery
porous silicon nanoparticles
BBB-on-a-chip
ligand density
organ-on-a-chip
nanomedicine
microfluidic model
neurodegenerative disorders
non-invasive delivery
device-related delivery
Alzheimer’s disease
Parkinson’s disease
ALS
Down syndrome
CNS disorders
nasal delivery
biologics
nose-to-brain
the blood–brain barrier
mesenchymal stem cell-based drug delivery
transmembrane drug delivery
n/a
thema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TD Industrial chemistry and manufacturing technologies::TDC Industrial chemistry and chemical engineering::TDCW Pharmaceutical chemistry and technology
topic_facet glioblastoma
focused ultrasound
blood-brain barrier
PET
SPECT
drug delivery
rotigotine
lecithin-chitosan hybrid nanoparticles
intranasal delivery
nose-to-brain uptake
brain distribution study
in vitro model
blood–brain barrier (BBB)
nanoparticles
targeted receptor-mediated transcytosis
ligand conjugation
nicotinic acetylcholine receptor
nanobody
VHH
transferrin receptor
receptor-mediated transcytosis
nanoparticle
liposome
extracellular vesicle
chemotherapy
targeted therapy
blood–brain barrier
brain tumor
glioma
cell-penetrating peptides (CPPs)
endosomal entrapment
homing peptides
tumour-specific markers
siRNA-CPP delivery
porous silicon nanoparticles
BBB-on-a-chip
ligand density
organ-on-a-chip
nanomedicine
microfluidic model
neurodegenerative disorders
non-invasive delivery
device-related delivery
Alzheimer’s disease
Parkinson’s disease
ALS
Down syndrome
CNS disorders
nasal delivery
biologics
nose-to-brain
the blood–brain barrier
mesenchymal stem cell-based drug delivery
transmembrane drug delivery
n/a
thema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TD Industrial chemistry and manufacturing technologies::TDC Industrial chemistry and chemical engineering::TDCW Pharmaceutical chemistry and technology
url ONIX_20240514_9783725806805_428